| abstract |
The present invention is represented by the general formula 5 '-( Me C x ) (T x ) Me C X A s A s t s c s c s a s t s g s g s Me C x A x ( G x ) (c) -3 'and preferably 5'- Me C x T x Me C x A s a s t s c s c s a s t s g s g s Me C x A x G x c-3' (Wherein capital letters represent LNA nucleotide analogues selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, and lowercase letters deoxy) Nucleotides, and the underline refers to one of the LNA nucleotide analogues or deoxynucleotides defined above). These LNA oligonucleotides exhibit very good properties in inhibiting survivin expression by anti-sense mechanisms, thereby reducing or inhibiting tumor in vivo. LNA oligonucleotides are superior to other LNA oligonucleotides targeting survivin mRNA when measured for functions such as apoptosis induction and inhibition of proliferation, and are effective in downregulating survivin mRNA and protein in transformed cancer cell lines. , When combined with Taxol, induces better apoptosis than other LNA oligonucleotides. |